ABIONYX Pharma announces new positive results in a uveitis model for the strategic development of the first class of biomedicines in ophthalmology based on its recombinant apoA-I

21.11.2023 - Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant human apoA-1, announces new positive ... Seite 1

Related Keywords

,Abionyx Pharma Share Chart ,Bionyx Pharma Share Kurs ,Bionyx Pharma Share Aktie ,